Vertex Pharmaceuticals (VRTX) Short Interest Ratio & Short Volume $450.00 +1.99 (+0.44%) (As of 09:15 AM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Vertex Pharmaceuticals Short Interest DataVertex Pharmaceuticals (VRTX) has a short interest of 4.50 million shares, representing 1.75% of the float (the number of shares available for trading by the public). This marks a 4.90% increase in short interest from the previous month. The short interest ratio (days to cover) is 4.3, indicating that it would take 4.3 days of the average trading volume of 1.18 million shares to cover all short positions.Current Short Interest4,500,000 sharesPrevious Short Interest4,290,000 sharesChange Vs. Previous Month+4.90%Dollar Volume Sold Short$2.14 billionShort Interest Ratio4.3 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares257,529,000 sharesFloat Size256,860,000 sharesShort Percent of Float1.75%Today's Trading Volume814 sharesAverage Trading Volume1,178,527 sharesToday's Volume Vs. Average0% Short Selling Vertex Pharmaceuticals? Sign up to receive the latest short interest report for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVRTX Short Interest Over TimeVRTX Days to Cover Over TimeVRTX Percentage of Float Shorted Over Time Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Vertex Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20244,500,000 shares $2.14 billion +4.9%1.8%4.3 $475.98 10/15/20244,290,000 shares $2.08 billion +5.2%1.7%4 $484.30 9/30/20244,080,000 shares $1.90 billion -6.0%1.6%3.7 $465.08 9/15/20244,340,000 shares $2.11 billion -0.9%1.7%3.8 $485.37 8/31/20244,380,000 shares $2.17 billion -0.9%1.7%3.8 $495.89 8/15/20244,420,000 shares $2.09 billion -13.0%1.7%3.7 $472.00 Get the Latest News and Ratings for VRTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 7/31/20245,080,000 shares $2.52 billion +23.3%2.0%4.2 $495.72 7/15/20244,120,000 shares $2.02 billion +0.5%1.6%3.5 $490.85 6/30/20244,100,000 shares $1.92 billion -8.3%1.6%3.5 $468.72 6/15/20244,470,000 shares $2.15 billion +2.8%1.7%4 $480.73 5/31/20244,350,000 shares $1.98 billion +15.4%1.7%4 $455.34 5/15/20243,770,000 shares $1.65 billion -2.6%1.5%3.6 $437.49 4/30/20243,870,000 shares $1.52 billion -4.0%1.5%3.7 $392.81 4/15/20244,030,000 shares $1.60 billion +1.3%1.6%3.3 $397.36 3/31/20243,980,000 shares $1.66 billion -3.6%1.6%3.1 $418.01 3/15/20244,130,000 shares $1.68 billion +2.0%1.6%3.3 $407.69 2/29/20244,050,000 shares $1.70 billion -1.9%1.6%2.8 $420.74 2/15/20244,130,000 shares $1.76 billion +24.8%1.6%2.8 $426.29 1/31/20243,310,000 shares $1.43 billion -1.2%1.3%2.1 $433.38 1/15/20243,350,000 shares $1.45 billion +2.8%1.3%2.3 $433.40 12/31/20233,260,000 shares $1.33 billion -8.2%1.3%2.3 $406.89 12/15/20233,550,000 shares $1.46 billion +32.0%1.4%2.5 $410.68 11/30/20232,690,000 shares $954.44 million +7.2%1.1%2.2 $354.81 11/15/20232,510,000 shares $876.84 million -3.5%1.0%2.2 $349.34 10/31/20232,600,000 shares $941.49 million -9.1%1.0%2.6 $362.11 10/15/20232,860,000 shares $1.06 billion +0.4%1.1%2.9 $371.00 9/30/20232,850,000 shares $991.06 million -0.4%1.1%2.9 $347.74 9/15/20232,860,000 shares $997.85 million -2.1%1.1%2.9 $348.90 8/31/20232,920,000 shares $1.02 billion +7.0%1.1%2.7 $348.34 8/15/20232,730,000 shares $954.90 million -4.6%1.1%2.2 $349.78 7/31/20232,860,000 shares $1.01 billion +13.9%1.1%2.3 $352.34 7/15/20232,510,000 shares $885.38 million -8.1%1.0%1.9 $352.74 6/30/20232,730,000 shares $960.71 million No Change1.1%2.2 $351.91 6/15/20232,730,000 shares $952.99 million -11.1%1.1%2.2 $349.08 5/31/20233,070,000 shares $993.36 million -5.0%1.2%2.6 $323.57 5/15/20233,230,000 shares $1.13 billion -0.3%1.3%3 $348.65 4/30/20233,240,000 shares $1.10 billion -4.1%1.3%2.9 $340.73 4/15/20233,380,000 shares $1.13 billion -3.4%1.3%2.9 $333.52 3/31/20233,500,000 shares $1.10 billion +19.9%1.4%2.8 $315.07 3/15/20232,920,000 shares $859.27 million +9.0%1.1%2.3 $294.27Bill Gates’ is about to mint millionaires (again) with Stargate. (Ad)This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.Click here and I’ll tell you everything you need to know. 2/28/20232,680,000 shares $777.98 million -4.3%1.1%2.1 $290.29 2/15/20232,800,000 shares $836.50 million -11.1%1.1%2 $298.75 1/31/20233,150,000 shares $1.02 billion +19.8%1.2%2.2 $323.10 1/15/20232,630,000 shares $791.47 million +5.2%1.0%1.8 $300.94 12/30/20222,500,000 shares $721.95 million -19.1%1.0%1.8 $288.78 12/15/20223,090,000 shares $952.96 million +10.0%1.2%2.1 $308.40 11/30/20222,810,000 shares $889.08 million -7.3%1.1%1.9 $316.40 11/15/20223,030,000 shares $925.00 million +6.7%1.2%2.2 $305.28 10/31/20222,840,000 shares $886.08 million -3.1%1.1%2.1 $312.00 10/15/20222,930,000 shares $859.11 million -5.8%1.2%2.2 $293.21 9/30/20223,110,000 shares $900.47 million +7.6%1.2%2.3 $289.54 9/15/20222,890,000 shares $831.37 million +2.1%1.1%2 $287.67 8/31/20222,830,000 shares $797.38 million +10.1%1.1%1.9 $281.76 8/15/20222,570,000 shares $785.21 million -24.9%1.0%1.6 $305.53 7/31/20223,420,000 shares $959.00 million -4.7%1.3%2 $280.41 7/15/20223,590,000 shares $1.05 billion +14.0%1.4%2.1 $292.84 6/30/20223,150,000 shares $887.64 million -7.9%1.2%1.8 $281.79 6/15/20223,420,000 shares $867.00 million -10.9%1.3%1.9 $253.51 5/31/20223,840,000 shares $1.03 billion +7.3%1.5%2.3 $268.65 5/15/20223,580,000 shares $883.26 million +5.0%1.4%2.2 $246.72 4/30/20223,410,000 shares $931.68 million -16.8%1.4%2.1 $273.22 4/15/20224,100,000 shares $1.18 billion +2.2%1.6%2.4 $287.97 3/31/20224,010,000 shares $1.05 billion +19.4%1.6%2.3 $260.97 3/15/20223,360,000 shares $829.89 million -6.4%1.3%2 $246.99 2/28/20223,590,000 shares $825.77 million +10.1%1.4%2.1 $230.02 2/15/20223,260,000 shares $760.92 million +8.7%1.3%1.7 $233.41 1/31/20223,000,000 shares $729.15 million -1.3%1.2%1.5 $243.05 1/15/20223,040,000 shares $711.54 million +4.5%1.2%1.6 $234.06 12/31/20212,910,000 shares $639.04 million -9.4%N/A0 $219.60 12/15/20213,210,000 shares $677.73 million +12.6%1.3%1.7 $211.13 11/30/20212,850,000 shares $532.78 million -1.7%1.1%1.6 $186.94 11/15/20212,900,000 shares $541.89 million -39.1%1.2%1.9 $186.86 10/29/20214,760,000 shares $880.27 million +7.2%1.9%2.9 $184.93 10/15/20214,440,000 shares $807.06 million -12.4%1.7%2.7 $181.77 9/30/20215,070,000 shares $919.65 million +2.2%2.0%2.8 $181.39 9/15/20214,960,000 shares $936.75 million +2.7%1.9%2.5 $188.86 8/31/20214,830,000 shares $967.40 million -4.2%1.9%2 $200.29 8/13/20215,040,000 shares $979.57 million +20.3%2.0%2.1 $194.36 7/30/20214,190,000 shares $844.62 million +2.4%1.6%1.8 $201.58 7/15/20214,090,000 shares $818.37 million +0.5%1.6%1.9 $200.09 6/30/20214,070,000 shares $820.63 million -10.0%1.6%1.9 $201.63 6/15/20214,520,000 shares $854.14 million +11.6%1.8%2.3 $188.97 5/28/20214,050,000 shares $844.95 million -1.5%1.6%2.5 $208.63 5/14/20214,110,000 shares $880.98 million -11.2%N/A2.5 $214.35 4/30/20214,630,000 shares $980.91 million -5.3%N/A2.5 $211.86 4/15/20214,890,000 shares $1.06 billion +15.1%N/A2.4 $217.13 3/31/20214,250,000 shares $905.21 million -14.7%N/A2.1 $212.99 3/15/20214,980,000 shares $1.07 billion +14.5%N/A2.5 $214.33 2/26/20214,350,000 shares $926.46 million +9.0%N/A2.2 $212.98 2/12/20213,990,000 shares $839.88 million +15.0%N/A2 $210.50Bill Gates’ is about to mint millionaires (again) with Stargate. (Ad)This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.Click here and I’ll tell you everything you need to know. 1/29/20213,470,000 shares $798.24 million +5.5%N/A1.8 $230.04 1/15/20213,290,000 shares $743.93 million -2.4%N/A1.8 $226.12 12/31/20203,370,000 shares $784.13 million +3.7%N/A1.6 $232.68 12/15/20203,250,000 shares $741.42 million +21.3%N/A1.5 $228.13 11/30/20202,680,000 shares $607.58 million -2.6%N/A1.3 $226.71 10/30/20202,920,000 shares $604.47 million -7.6%N/A1.6 $207.01 10/15/20203,160,000 shares $857.81 million -6.8%N/A1.9 $271.46 9/30/20203,390,000 shares $922.49 million +11.5%N/A2.7 $272.12 9/15/20203,040,000 shares $811.22 million -9.3%N/A2.3 $266.85 8/31/20203,350,000 shares $935.05 million +4.0%N/A2.4 $279.12 8/14/20203,220,000 shares $860.67 million -4.2%N/A2 $267.29 7/31/20203,360,000 shares $913.92 million -17.0%N/A2 $272.00 7/15/20204,050,000 shares $1.19 billion -6.5%N/A2.2 $293.83 6/30/20204,330,000 shares $1.26 billion +2.9%N/A2.2 $290.31 6/15/20204,210,000 shares $1.13 billion +7.7%N/A2 $267.77 5/29/20203,910,000 shares $1.08 billion -1.5%N/A1.7 $277.38 5/15/20203,970,000 shares $1.15 billion +2.6%N/A1.8 $288.69 4/30/20203,870,000 shares $972.14 million +13.2%N/A1.8 $251.20 4/15/20203,420,000 shares $872.89 million -14.9%N/A1.7 $255.23 3/31/20204,020,000 shares $956.56 million +29.4%N/A2.1 $237.95 3/13/20203,107,300 shares $766.29 million +7.9%N/A1.6 $246.61 2/28/20202,880,000 shares $582.36 million +9.5%N/A2 $202.21 2/14/20202,630,000 shares $606.24 million -16.2%N/A1.9 $230.51 1/31/20203,140,000 shares $728.61 million -11.6%N/A2.4 $232.04 1/15/20203,550,000 shares $879.73 million -1.1%N/A2.7 $247.81 12/31/20193,590,000 shares $822.33 million -0.8%N/A2.7 $229.06 VRTX Short Interest - Frequently Asked Questions What is Vertex Pharmaceuticals' current short interest? Short interest is the volume of Vertex Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 4,500,000 shares of VRTX short. 1.75% of Vertex Pharmaceuticals' shares are currently sold short. Learn More on Vertex Pharmaceuticals' current short interest. What is a good short interest ratio for Vertex Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VRTX shares currently have a short interest ratio of 4.0. Learn More on Vertex Pharmaceuticals's short interest ratio. Which institutional investors are shorting Vertex Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Vertex Pharmaceuticals: Barclays PLC, Jane Street Group LLC, Wolverine Trading LLC, Readystate Asset Management LP, Point72 DIFC Ltd, Ikarian Capital LLC, Centiva Capital LP, Paloma Partners Management Co, Verition Fund Management LLC, Capstone Investment Advisors LLC, Walleye Trading LLC, Walleye Capital LLC, PEAK6 Investments LLC, BNP Paribas Financial Markets, Citigroup Inc., Wolverine Asset Management LLC, Genus Capital Management Inc., IMC Chicago LLC, New Harbor Financial Group LLC, Concourse Financial Group Securities Inc., and Cubist Systematic Strategies LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Vertex Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.75% of Vertex Pharmaceuticals' floating shares are currently sold short. Is Vertex Pharmaceuticals' short interest increasing or decreasing? Vertex Pharmaceuticals saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 4,500,000 shares, an increase of 4.9% from the previous total of 4,290,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Vertex Pharmaceuticals' float size? Vertex Pharmaceuticals currently has issued a total of 257,529,000 shares. Some of Vertex Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Vertex Pharmaceuticals currently has a public float of 256,860,000 shares. How does Vertex Pharmaceuticals' short interest compare to its competitors? 1.75% of Vertex Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies compare to Vertex Pharmaceuticals: Amgen Inc. (1.64%), Gilead Sciences, Inc. (1.43%), Regeneron Pharmaceuticals, Inc. (1.68%), Alnylam Pharmaceuticals, Inc. (2.87%), Biogen Inc. (2.16%), BeiGene, Ltd. (1.12%), United Therapeutics Co. (5.24%), Incyte Co. (3.90%), Royalty Pharma plc (3.84%), BioMarin Pharmaceutical Inc. (2.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Vertex Pharmaceuticals stock? Short selling VRTX is an investing strategy that aims to generate trading profit from Vertex Pharmaceuticals as its price is falling. VRTX shares are trading down $19.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Vertex Pharmaceuticals? A short squeeze for Vertex Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of VRTX, which in turn drives the price of the stock up even further. How often is Vertex Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VRTX, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies AMGN Short Squeeze GILD Short Squeeze REGN Short Squeeze ALNY Short Squeeze BIIB Short Squeeze BGNE Short Squeeze UTHR Short Squeeze INCY Short Squeeze RPRX Short Squeeze BMRN Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VRTX) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersAmazon's $150B Data Center Bet—What It Means for Uranium InvestorsAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With dem...The Bull Report | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredFormer CIA Advisor: Stock Market Miracle! Trump’s “Project Independence”Jim says fast-movers who act now could have the chance to turn as little as $10,000 into $265,000 by Inaugurat...Paradigm Press | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredAmerica’s Pro-Crypto AgendaCash In On the Pro-Crypto America 27 experts reveal their top picks for 2025 Crypto 101 Media | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
